Nutriband Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Nutriband Inc Unternehmen

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Nutriband Inc Informationen



BörsenkürzelNTRB

Name des UnternehmensNutriband Inc

IPO-datumJun 20, 2017

CEOMelnik (Serguei)

Anzahl der mitarbeiter- -

WertpapierartOrdinary Share

GeschäftsjahresendeJun 20

Addresse121 S Orange Ave Ste 1500

StadtORLANDO

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl32801-3241

Telefon14073776695

Websitehttps://nutriband.com/

BörsenkürzelNTRB

IPO-datumJun 20, 2017

CEOMelnik (Serguei)

Führungskräfte von Nutriband Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Serguei Melnik

Chairman of the Board, President, Interim Chief Executive Officer, Secretary

939.42K

+119000.00%

Mr. Gerald Goodman

Chief Financial Officer

86.33K

--

Dr. Jeff Patrick, Pharm.D.

Chief Scientific Officer

36.61K

--

Mr. Radu Bujoreanu

Independent Director

15.75K

--

Mr. Mark Hamilton

Independent Director

13.96K

-3249.00%

Ms. Irina Gram

Independent Director

1.17K

--

Dr. Alan Smith, Ph.D.

Chief Operating Officer, President of 4P Therapeutics

--

Prof. Dr. Stefani C. Mancas

Independent Director

--

Mr. Sergei Glinka

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Serguei Melnik

Chairman of the Board, President, Interim Chief Executive Officer, Secretary

939.42K

+119000.00%

Mr. Gerald Goodman

Chief Financial Officer

86.33K

--

Dr. Jeff Patrick, Pharm.D.

Chief Scientific Officer

36.61K

--

Mr. Radu Bujoreanu

Independent Director

15.75K

--

Mr. Mark Hamilton

Independent Director

13.96K

-3249.00%

Ms. Irina Gram

Independent Director

1.17K

--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2026Q3

FY2026Q2

FY2026Q1

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Sale of goods

346.06K

0.00%

Services

0.00

0.00%

Nach RegionUSD

Name

Umsatz

Anteil

United States

346.06K

100.00%

Non-United States

0.00

0.00%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Sale of goods

346.06K

0.00%

Services

0.00

0.00%

Aktionärsstatistik

Aktualisiert: Sat, Jan 31

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Botgros (Vitalie)

26.44%

TII Jet Services, LDA

14.85%

Sheridan (Gareth)

14.47%

Glinka (Serguei)

9.19%

Melnik (Serguei)

7.72%

Andere

27.33%

Aktionäre

Anteil

Botgros (Vitalie)

26.44%

TII Jet Services, LDA

14.85%

Sheridan (Gareth)

14.47%

Glinka (Serguei)

9.19%

Melnik (Serguei)

7.72%

Andere

27.33%

Aktionärstypen

Aktionäre

Anteil

Individual Investor

59.53%

Corporation

14.85%

Investment Advisor

2.06%

Investment Advisor/Hedge Fund

0.82%

Research Firm

0.04%

Andere

22.70%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

40

355.48K

2.92%

-101.91K

2025Q3

36

350.65K

2.91%

-71.29K

2025Q2

44

8.87M

79.52%

+489.89K

2025Q1

43

8.13M

73.14%

+1.78M

2024Q4

40

8.04M

72.39%

+1.68M

2024Q3

40

8.08M

72.79%

+1.82M

2024Q2

38

5.19M

52.25%

+2.18M

2024Q1

34

4.36M

55.65%

+1.38M

2023Q4

30

4.30M

54.90%

+1.31M

2023Q3

29

2.96M

37.78%

-39.44K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Botgros (Vitalie)

3.22M

26.44%

+132.25K

+4.28%

Dec 17, 2025

TII Jet Services, LDA

1.81M

14.85%

+485.05K

+36.66%

Sep 01, 2024

Sheridan (Gareth)

1.76M

14.47%

--

Dec 17, 2025

Glinka (Serguei)

1.12M

9.19%

+294.04K

+35.64%

Dec 17, 2025

Melnik (Serguei)

939.42K

7.72%

+119.00K

+14.50%

Dec 17, 2025

The Vanguard Group, Inc.

202.74K

1.67%

+3.11K

+1.56%

Sep 30, 2025

Goodman (Gerald)

86.33K

0.71%

--

Dec 17, 2025

Geode Capital Management, L.L.C.

59.94K

0.49%

-3.69K

-5.80%

Sep 30, 2025

Smith (Allan)

36.91K

0.3%

-5.00K

-11.93%

Dec 17, 2025

Patrick (Jeff)

36.61K

0.3%

--

Dec 17, 2025

Verbundene ETFs



Aktualisiert: Tue, Dec 2

Name

Anteil

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Jul 29, 2022

Split

6→7

Datum

Ex-Dividendentag

Art

Verhältnis

Jul 29, 2022

Split

6→7